This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Ramasubbu, K. Articles by Mann, D. L. Search for Related Content PubMed Articles by Ramasubbu, K. Articles by Mann, D. L.

STATE-OF-THE-ART PAPER

Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy

Kumudha Ramasubbu, MD^_*, Jerry Estep, MD^_*, Donna L. White, PhD, MPH, Anita Deswal, MD, MPH^_*,, and Douglas L. Mann, MD^_*,_*

^_* Section of Cardiology and the Winters Center for Heart Failure Research, Department of Medicine, Baylor College of Medicine and The Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, Texas
Houston Center for Quality of Care and Utilization Studies, Houston, Texas
Section of Cardiology, Michael E. DeBakey VA Medical Center, Houston, Texas.

Manuscript received July 2, 2007; revised manuscript received October 1, 2007, accepted October 2, 2007.

^_* Reprint requests and correspondence: Dr. Douglas L. Mann, Section of Cardiology, 1709 Dryden Road, BCM602, F.C. 9.83, Houston, Texas 77030. (Email: dmann{at}bcm.tmc.edu).

Over the past 2 decades our understanding of the pathologic mechanisms that lead to heart failure (HF) has evolved from simplistic hemodynamic models to more complex models that have implicated neurohormonal activation and adverse cardiac remodeling as important mechanisms of disease progression. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become a standard part of the armamentarium in the prevention and treatment of coronary artery disease. Apart from their lipid-lowering capabilities, statins seem to have non–lipid-lowering effects that impact neurohormonal activation and cardiac remodeling. This review will examine the potential benefits of statins in HF patients with ischemic and nonischemic cardiomyopathy as well as potential concerns regarding the use of statins in these patients.

Abbreviations and Acronyms   CI = confidence interval   CoQ10 = coenzyme Q10   eNOS = endothelial nitric oxide synthase   EPC = endothelial progenitor cell   HF = heart failure   HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A   HR = hazard ratio   LV = left ventricular   LVEDD = left ventricular end-diastolic dimension   LVEF = left ventricular ejection fraction   NADPH = nicotinamide adenine dinucleotide phosphate   NO = nitric oxide   NYHA = New York Heart Association   PI3K/Akt = phosphatidylinositol-3 kinase-Akt

This article has been cited by other articles:

				G. Suzuki, V. Iyer, T. Cimato, and J. M. Canty Jr Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133+ and cKit+ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle Circ. Res., January 30, 2009; 104(2): 255 - 264. [Abstract] [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]